Coherus BioSciences Announces New Employment Inducement Grants
April 19 2019 - 9:30AM
Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that
effective April 18, 2019, the compensation committee of the
company’s board of directors granted six new employees, a Senior
Vice President, and another Senior Vice President, options to
purchase an aggregate of 95,000 shares, 100,000 shares and 100,000
shares of the company’s common stock, respectively, with a per
share exercise price of $14.71, the closing trading price on the
grant date.
The stock options were granted pursuant to the Coherus
BioSciences, Inc. 2016 Employment Commencement Incentive Plan,
which was approved by the company’s board of directors in June 2016
under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity
grants to induce new employees to enter into employment with the
company.
About Coherus BioSciences, Inc.
Coherus BioSciences is a leading biosimilar company that
develops and commercializes high-quality therapeutics for major
regulated markets. Biosimilars are intended for use in place of
existing, branded biologics to treat a range of chronic and often
life-threatening diseases, with the potential to reduce costs and
expand patient access. Composed of a team of proven industry
veterans with world-class expertise in process science, analytical
characterization, protein production, sales and marketing and
clinical-regulatory development, Coherus BioSciences is positioned
as a leader in the global biosimilar marketplace. Coherus
BioSciences commercializes UDENYCA™ (pegfilgrastim-cbqv) in the
U.S. and has received regulatory approval for UDENYCA™ in the
European Union. Coherus BioSciences is advancing two late-stage
clinical products towards commercialization, CHS-1420 (adalimumab
biosimilar) and CHS-0214 (etanercept biosimilar), and developing a
robust pipeline of future products in ophthalmology (including
CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept
biosimilar), as well as CHS-131, a small molecule for nonalcoholic
steatohepatitis (NASH) and multiple sclerosis. For additional
information, please visit www.coherus.com.
Contact
David S. ArringtonVP, Investor Relations & Corporate
AffairsCoherus BioSciences, Inc.darrington@coherus.com+1 (650)
395-0196
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Apr 2023 to Apr 2024